ASSERTIO HOLDINGS INC

Merger‑Minded Exit at Assertio Holdings: insider sales reveal strategic cash‑out, a $23.50 share payout, and Zydus’ expansion into U.S. oral‑medicine markets.

Insightful report on Assertio Holdings insider trades: Mason Heather L.’s neutral buy‑sell cycle amid Zydus acquisition shows stable confidence and strong post‑merger outlook.

Assertio insider buying surge signals confidence ahead of its Garda Therapeutics merger – discover how a reverse split, tender‑offer delay, and strategic alignment could boost investor value and market outlook.